PI
CRL icon

PEAK6 Investments’s Charles River Laboratories CRL Stock Holding History

PEAK6 Investments’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,800
Closed -$2.44M – 3583
2024
Q2 		$2.44M Buy
+11,800
New +$2.67M 0.01% 1238
2024
Q1 		– Sell
-8,100
Closed -$1.91M – 4138
2023
Q4 		$1.91M Buy
+8,100
New +$1.59M 0.01% 1556
2023
Q3 		– Sell
-900
Closed -$189K – 4125
2023
Q2 		$189K Sell
900
-1,500
-63% -$298K ﹤0.01% 2913
2023
Q1 		$484K Buy
2,400
+1,100
+85% +$249K ﹤0.01% 2419
2022
Q4 		$283K Sell
1,300
-2,700
-68% -$590K ﹤0.01% 3017
2022
Q3 		$787K Buy
4,000
+1,100
+38% +$237K ﹤0.01% 2432
2022
Q2 		$617K Buy
2,900
+2,700
+1,350% +$660K ﹤0.01% 3592
2022
Q1 		$57K Buy
+200
New +$61.7K ﹤0.01% 4506
2021
Q4 		– Sell
-36,400
Closed -$15M – 5197
2021
Q3 		$15M Sell
36,400
-4,700
-11% -$1.95M 0.03% 498
2021
Q2 		$15.2M Sell
41,100
-5,800
-12% -$1.94M 0.04% 485
2021
Q1 		$13.6M Buy
46,900
+33,700
+255% +$9.37M 0.03% 492
2020
Q4 		$3.3M Sell
13,200
-43,900
-77% -$10.5M 0.01% 1424
2020
Q3 		$12.9M Buy
57,100
+14,700
+35% +$3.05M 0.03% 476
2020
Q2 		$7.39M Buy
42,400
+41,300
+3,755% +$6.59M 0.03% 607
2020
Q1 		$139K Buy
+1,100
New +$165K ﹤0.01% 3108
2019
Q4 		– Sell
-700
Closed -$93K – 3486
2019
Q3 		$93K Sell
700
-1,800
-72% -$241K ﹤0.01% 3245
2019
Q2 		$355K Buy
2,500
+2,400
+2,400% +$326K ﹤0.01% 2517
2019
Q1 		$15K Sell
100
-21,900
-100% -$2.88M ﹤0.01% 3592
2018
Q4 		$2.49M Sell
22,000
-43,400
-66% -$5.43M 0.02% 1078
2018
Q3 		$8.8M Buy
+65,400
New +$8.07M 0.04% 521

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

PEAK6 Investments's CRL Position: Q3 2024 in Review

PEAK6 Investments sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 8,932 shares — an estimated $1.85M sold.

PEAK6 Investments first reported a position in CRL in Q4 2018 and held it in 19 quarters. The position peaked at $17.2M in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • PEAK6 Investments reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • PEAK6 Investments sold 8,932 Charles River Laboratories shares in Q3 2024, an estimated $1.85M.
  • PEAK6 Investments first reported a position in Charles River Laboratories in Q4 2018 and held it in 19 quarters.
  • PEAK6 Investments's Charles River Laboratories position peaked at $17.2M in Q3 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.